Purified herpes simplex thymidine kinase retroviral particles. II. Influence of clinical parameters and bystander killing mechanisms.
High-titer, purified herpes simplex virus thymidine kinase (HSV-TK) retroviral particles, followed with intraperitoneal ganciclovir (GCV) were tested in Fischer rats bearing 1-week established 9L gliosarcomas. 9L cells were infused intracranially through a cannula on day 0, given intracranial infusions of HSV-TK retroviral particles on days 7-12, and given 5 or 10 daily doses of intraperitoneal GCV starting at day 14. Tumor volumetric studies performed on rat brains at day 26 after tumor infusion revealed significant differences in experimental groups receiving HSV-TK retroviral particles plus 10-day GCV or the 100% transduced 9L-TK group receiving GCV versus control groups treated with either buffer, HSV-TK vector, or either 5- or 10-day regimens of GCV alone. The duration of GCV administration and the volume of tumor burden influenced efficacy. Adjuvant dexamethasone did not significantly affect efficacy. Experiments in which 9L rechallenge of animals treated with 9L-TK/GCV or 9L tumors treated with HSV-TK vector/GCV indicated that a host immune response was involved in rejecting the rechallenge tumor. Outcome was dependent upon the site and size of the rechallenge inoculum. In vitro, bystander effects were significant but were especially marked when cell-to-cell contact was maintained. Cumulatively, the data indicate that both the bystander effect and the host immune response are responsible for the efficacy observed in the suicide gene therapy paradigm using purified HSV-TK retroviral particles and GCV to treat smaller tumor burden in rats with 9L gliosarcoma.
Kruse
C A
CA
Department of Immunology, University of Colorado Health Sciences Center, Denver 80262, USA.
Lamb
C
C
Hogan
S
S
Smiley
W R
WR
Kleinschmidt-Demasters
B K
BK
Burrows
F J
FJ
D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D001254:Astrocytoma / Q000401:mortality / Q000628:therapy; D001932:Brain Neoplasms / Q000401:mortality / Q000628:therapy*; D003907:Dexamethasone / Q000627:therapeutic use; D015774:Ganciclovir / Q000627:therapeutic use; D015316:Genetic Therapy; D005909:Glioblastoma / Q000401:mortality / Q000628:therapy*; D018259:Herpesvirus 1, Human / Q000201:enzymology; D008297:Male; D009368:Neoplasm Transplantation; D051381:Rats; D011916:Rats, Inbred F344; D012190:Retroviridae / Q000235:genetics*; D013256:Steroids / Q000008:administration & dosage / Q000627:therapeutic use; D013937:Thymidine Kinase / Q000235:genetics* / Q000302:isolation & purification / Q000378:metabolism; D014407:Tumor Cells, Cultured; D014771:Virion
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D013256:Steroids; D003907:Dexamethasone; D013937:Thymidine Kinase; D015774:Ganciclovir